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Summary For the presentation of peptide antigens to cytotoxic CD8+ T lymphocytes of the immune system, the expression of human
leukocyte antigen (HLA) class I molecules on the cell surface is necessary. There is increasing evidence that surface HLA class antigen
expression is altered in a variety of human tumours by either loss or down-regulation of these molecules, which may be a strategy for evasion
of immunosurveillance by malignant cells. This study has examined the expression of HLA class molecules in head and neck squamous cell
carcinoma (HNSCC) specimens by immunohistochemistry, using a wide panel of antibodies directed against allele-specific as well as
monomorphic determinants of these molecules. The expression of TAP proteins, HLA-DR and the co-stimulatory molecule ICAM-1 were also
studied. In addition, the expression of the tumour-associated antigens (TAA) p53 and MAGE genes was determined. Aberrant allelic
expression of HLA class antigens was detected in 17 out of 34 (50%) of the specimens stained, whereas HLA class I expression determined
by W6/32 staining was found to be heterogeneous in only 2 out of 34 (6%) cases. Decreased expression of ICAM-1 was observed in 12 out
of 34 (35%) tumour specimens and de novo expression of HLA-DR (HLA class 11) by carcinoma cells in 13 out of 34 (38%) cases. Aberrant
expression of HLA class I antigens was frequently observed in cases in which MAGE genes and p53 overexpression were detected. The
altered expression of these immunomodulatory molecules in HNSCC may affect prognosis and has important implications for peptide-based
immunotherapy strategies for these patients.
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For the presentation ofantigenic peptides to T-cells ofthe immune
system, the presence ofmajor histocompatibility complex (MHC)
molecules are required on the cell surface. These molecules are
encoded by a large number ofgenes located on chromosome 6p in
humans, termed the human leucocyte antigen (HLA) system
(Parham and Ohta, 1996). The 'classical' HLA class I molecules
(HLA-A, -B, -C) act as antigen presenters to CD8+ cytotoxic T
lymphocytes (CTLs) and, for their stable cell-surface expression,
are composed of: a highly polymorphic 45-kDa membrane-bound
glycoprotein a-chain; a processed peptide of 8-10 amino acids
bound within the al and a2 helices of the a-chain; and a non-
covalently linked 12-kDa protein, ,B2-microglobulin (encoded on
chromosome 15 in humans). Classical HLA class I molecules are
usually expressed on all normal human nucleated cells, except for
spermatozoa, oocytes and trophoblast cells of the human placenta
(Restifo and Wunderlich, 1995). Antigen processing is necessary
for the expression ofclass I molecules on the cell surface. Peptide
fragments derived from intracellular proteins are produced by the
action of the proteasome and are then transported into the endo-
plasmic reticulum (ER) by peptide transporter proteins, such as
Received 9 October 1996
Revised20January 1997
Accepted 19 February 1997
Correspondence to: AK Murray
TAP (the product of the TAP-IITAP-2 genes located within the
MHC class II region), where synthesis of fully assembled tri-
molecular HLA class I complexes occurs, before transport to the
cell surface via the Golgi apparatus (York and Rock, 1996).
HLA class II molecules (HLA-DP, -DQ, -DR) act as antigen
presenters for CD4+ lymphocytes, normally being present on B-
lymphocytes, macrophages, Langerhans dendritic cells, follicular
dendritic cells, some thymocytes, activated T-cells and epithelial
cells (Janeway and Travers, 1994). These molecules are composed
of a heterodimer of a non-covalently linked 34-kDa a-chain and a
28-kDa n-chain, both of which are integral membrane glycopro-
teins. Peptides forbinding to class II molecules (approximately 13
amino acids long) areusually produced from extracellular antigens
via the endosomal pathway and lie within the peptide binding
groove produced by the polymorphic al and , helices (Neefjes
and Ploegh, 1992).
For T-cell stimulation, not only is the presence ofpeptide-MHC
complexes necessary on the cell surface, but also the presence of
co-stimulatory molecules, such as ICAM-1 (CD54), the B7/CD80
family and cytokines (e.g. interleukin 2, interleukin 4). Triggering
the T-cell receptor (TCR) by the antigen-MHC complex alone may
not produce a T-cell response, with anergy or death by apoptosis
being produced instead (June et al, 1994).
There is evidence that the immune system is active against
tumours. Immunosuppressedpeople (e.g. HIV infectedorpatients on
immunosuppressant drugs aftertransplants) are atriskofdeveloping
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Table 1 Sites, stage groups and grades of head and neck squamous cell
carcinoma specimens used
Specimen characteristic n
Site
Oral cavity
Pharynx
Larynx
Parotid
Facial skin
Maxillary sinus
Cervical nodes
Total
2
12
9
1
1
8
34
Stage group
11
III
IV
Total
Grade
Dysplasiaa
Basaloid
Well differentiated
Moderately differentiated
Poorly differentiated
Total
2
2
7
23
34
6
16
10
34
aBecause of multiple recurrences, a clinical suspicion of verrucous type SCC
was held for this patient.
tumours that occasionally regress once immunocompetence is
restored (loachim, 1990). Spontaneous regression of tumours (that
can occur in cutaneous melanoma, for example), the isolation of
cytotoxic immune cells from tumour-infiltrating lymphocytes (TILs)
or peripheral blood lymphocytes (PBLs) that can kill autologous
tumour cells in vitro and the presence ofantibodies against tumour-
associated antigens in the sera ofcancer patients are all evidence for
tumour immunosurveillance (Graubert and Ley, 1996).
Overexpressed or mutant oncogene and tumour-suppressor gene
protein products, such as the epidermal growth factor receptor
(EGFR), HER-2/neu, c-myc, p2lras, cyclins and p53, viral
proteins (e.g. derived from human papillomavirus, HPV) and reac-
tivated embryonal gene products (e.g. MAGE gene family) are
potential tumour-associated antigens (TAAs) that could be targeted
in immunotherapy strategies (Pardoll, 1993; Boon et al, 1995).
However, as T-cell responses are MHC restricted, the expres-
sion of HLA class I-peptide complexes in conjunction with co-
stimulatory molecules and/or cytokines is needed to present and
stimulate a cytotoxic CD8+ CTL response against immunogenic
peptides derived from TAAs. With the development ofmonoclonal
antibodies that recognize HLA molecules, immunohistochemical
studies in a number oftumour systems have shown that malignant
cells often have decreased expression of HLA class I molecules
and/or de novo expression of class II molecules (Garrido et al,
1993). As the expression of these molecules influences T-cell
responses, then any alterations may have important consequences
for tumour immunosurveillance and may influence the outcome of
the disease.
The use of allele-specific monoclonal antibodies against HLA
class I molecules has demonstrated higher frequencies of aberrant
expression in tumour cells compared with the use of antibodies
Table 2 Antibodies used in this study obtained from the HLA and Cancer
Committee of the 12th International Histocompatibility Workshop and
Conference
Antibodyname Specificity Origin and isotype Dilution used
GRH-1 fB2m Mouse IgGl 1:200
NAMB-1 J32m Mouse IgGl 1:50
L368 P2m Mouse IgGl 1:20
BBM-1 P2m Mouse IgG2 1:50
W6/32 P2m+ heavy chain MouselgG2 1:100
1082C5 HLA-A locus Mouse IgGl 1:100
LGIII-220.6 HLA-A locus Mouse IgGl 1:20
A131 HLA-A locus Mouse IgG 1:10 000
YTH HLA-B locus Mouse IgG 1:20 000
Q6/64 HLA-B locus Mouse IgG2 1:200
H2-89-1 HLA-B locus Mouse IgG2 1:50
HC-10 HLA-B/C loci Mouse IgG2 1:50
MA2.1 HLA-A2,-B17 Mouse IgGl 1:10
Kre501 HLA-A2,-28 Mouse IgG2 1:50
CR11-351 HLA-A2,-28 Mouse IgGl 1:20
HO-4 HLA-A2,-28 Mouse IgGl 1:10
KS-1 HLA-A2,-28 Mouse IgGl 1:50
BB7.2 HLA-A2,-69 Mouse IgG2 1:50
160-30 HLA-A3 Mouse IgG2 1:20
361-1 HLA-A3 Mouse IgM Neat
LT129.11 HLA-A30,-31 Mouse IgG2 1:50
BB7.1 HLA-B7 Mouse IgGl 1:50
KS-4 HLA-B7 Mouse IgG2 1:20
MRE-4 HLA-B8 Mouse IgG2 1: 5000
375-1 HLA-B13 Mouse IgM Neat
116-5-28 HLA-Bw4 Mouse IgG2 1:20
126.39 HLA-Bw6 Mouse IgG3 1:20
SV94-297 TAP-1 Rabbit anti-serum 1:100
SV94-299 TAP-2 Rabbit anti-serum 1:100
34-1-2 Negative control Mouse IgG2 1:10
6B4 Negative control Mouse IgGl 1:10
31-3-4 Negative control Mouse IgM 1:5
targeted against monomorphic determinants of HLA molecules
(Kaklamanis et al, 1995; Keating et al, 1995; Korkolopoulou et al,
1996). Previous studies on HLA expression in HNSCC (Esteban et
al, 1989; Houck et al, 1990; Mattijsen et al, 1991), though, have
not used a wide panel of allele-specific monoclonal antibodies.
Hence, the aims of this study were to examine HLA class I allele
expression by immunohistochemistry in frozen HNSCC speci-
mens using a wide panel ofantibodies obtained from the HLA and
Cancer Committee of the 12th International Histocompatibility
Workshop and Conference. In addition, the expression of HLA-
DR, ICAM-1, the TAP proteins involved in the HLA class I
antigen processing pathway and the potential TAA p53 was
studied. Information on MAGE gene expression obtained by
reverse transcription polymerase chain reaction was also available
for these tumour specimens.
MATERIALS AND METHODS
Patients and tumour specimens
In total, 34 head and neck squamous cell carcinoma tissue speci-
mens were available for use. Specimens were obtained from
consenting patients undergoing surgical resection of their tumours
at the Royal Hallamshire Hospital, Glossop Road, Sheffield, UK.
Specimens were snap frozen in liquid nitrogen and stored at-80°C.
In four cases, associated lymph node metastases were also avail-
able. Three samples ofadjacent normal mucosa were also stained.
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Table 3 HLA antigen expression in head and neck squamous cell
carcinoma specimens determined by immunohistochemistry
Determinant Positive Positive
stromal tumour
stain expression
W6/32 34/34 32/34
HLA A/B/C (94)
P2-Microglobulin 34/34 30/34
(88)
HLA-A locus 34/34 30/34
(88)
HLA-B locus 34/34 32/34
(94)
HLA-B/C loci 34/34 30/34
(88)
TAP-1 34/34 32/34
(94)
TAP-2 34/34 34/34
(100)
HLA-A1 4/34 3/4
(12) (75)
HLA-A2 18/34 12/18
(53) (67)
HLA-A3 6/34 2/6
(18) (33)
HLA-A28 2/34 2/2
(6) (100)
HLA-A30/A31 4/34 3/4
(12) (75)
HLA-B7 10/34 2/10
(29) (20)
HLA-B8 11/33 9/11
(33) (82)
HLA-B13 2/34 2/2
(6) (100)
HLA-B17 2/34 1/2
(6) (50)
HLA-Bw4 27/34 23/27
(79) (85)
HLA-Bw6 29/34 26/29
(85) (90)
HLA-DR 34/34 9/34
(HLA class 11) (26)
ICAM-1 34/34 22/34
(65)
Heterogeneous
tumour
expression
2/34
(6)
4/34
(12)
4/34
(12)
2/34
(6)
4/34
(12)
2/34
(6)
0/34
0/4
4/18
(22)
0/6
0/2
1/4
(25)
5/10
(50)
2/11
(18)
0/2
1/2
(50)
3/27
(11)
2/29
(7)
4/34
(12)
7/34
(20)
Negative
tumour
expression
0/34
0/34
0/34
0/34
used at a dilution of 1:5. A mouse IgG anti-ICAM-1 antibody was
a kind gift from Dr N Hogg (ICRF, London) and was used at
1:100. The following antibodies were purchased from Dako (High
Wycombe, UK): anti-HLA-DR (clone DK22, mouse IgG2a, 1:100
dilution), pan-cytokeratin 5/6/8/17/19 (clone MNF116, mouse
IgGI, 1:50 dilution) and anti-p53 protein (clone D07, mouse
IgG2b, 1:100).
All antibodies were stored at 4'C and were diluted with sterile
phosphate-buffered saline (PBS) before use. Optimization was
performed using cytospins of HLA-typed lymphoblastoid cell
lines kindly provided by Dr Gelsthorpe (Blood Transfusion
Service, Sheffield).
0/34
0/34
0/34
Antigen frequency in Caucasians: HLA-A1, 26.4%; HLA-A2, 49.4%; HLA-A3,
24.7%; HLA-A28, 9.2%; HLA-A30, 6.9%; HLA-A31, 5.7%; HLA-B7, 21.7%;
HLA-B8, 18.3%; HLA-B 13, 5.7%; HLA-B17, 5.7%. Percentage figures for
staining have been rounded up to the nearest integer. Numbers in
parentheses are percentages.
The sites, stage grouping and grades of the tumour specimens
used in this study are shown in Table 1, with all staging carried out
according to guidelines laid out in the American Joint Committee
on Cancer Manualfor Staging Cancer (1992 edition). Of the 34
patients, 30 were male and four were female, with an age range of
49-83 years (mean age 64 years).
Antibodies
The anti-HLA class I antibodies obtained from the HLA and
Cancer Committee of the 12th International Histocompatibility
Workshop and Conference are shown in Table 2, with their speci-
ficity, isotype and dilution used. In addition, an anti-HLA-A1
mouse IgM monoclonal antibody (6B11) was a kind gift from Dr
Stefan Carrel (Ludwig Institute, Lausanne, Switzerland) and was
Immunohistochemistry
Seven-micrometre sections were cut using a cryostat (Bright
Instruments, Cambridgeshire, UK), placed onto APES (Sigma-
Aldrich, Poole, UK) coated slides and left to air dry before fixation
in 100% acetone (BDH Merck, Lutterworth, UK) for 10minatroom
temperature. Fixed sections were then stored at-20°C until use.
All sections cut were stained with haematoxylin and eosin, as
well as for cytokeratin, to identify tumour tissue.
A three-stage immunoperoxidase technique was performed using
aVectastain Elite ABC kit (mouse IgG), aVectastain ABC kit (rabbit
IgG) and a biotinylated goat anti-mouse IgM antibody all purchased
from Vector Laboratories (Peterborough, UK). Visualization of
peroxidase was performed using a DAB (3,3'-diaminobenzidine)
substrate kit also purchased from Vector Laboratories.
Briefly, tumour specimens were thawed, isolated with a PAP
pen (The Binding Site, Birmingham, UK) and rehydrated with
PBS before the application ofblocking serum for 30 min at room
temperature. Primary diluted antibody was applied after tapping
off the blocking serum and was incubated for 1 hour at room
temperature in a humidified chamber. After washing twice with
running PBS, diluted biotinylated secondary antibody was then
applied for 30 min and, after further washing in PBS, ABC
(avidin-biotin complex) reagent was placed over the specimens
for 30 min. Any unbound reagent was removed by washing in
PBS, with bound peroxidase visualized using DAB solution left
for 10-15 min for a brown precipitate to develop. Sections were
then washed in tap water, counterstained in Harris's haematoxylin
(BDH Merck) for 20-30 s, washed and then dehydrated through
graded alcohols before clearing in xylene and mounting under
glass coverslips using DePeX mounting medium (BDH Merck).
Slides were initially analysed and graded independently by two
investigators using a Leitz Dialux light microscope. In case of a
difference of more than 10%, consensus could be reached during
joint evaluation. Tumour and surrounding stroma were graded as
follows: positive, greaterthan 75% ofcells stained; heterogeneous,
20-75% of cells stained, with per cent positive given to nearest
10%; and negative, less than 20% ofcells positive.
As the patients were not HLA typed, the surrounding stroma
acted as an internal positive control and was used to detect antigen
loss in tumour specimens. In all staining runs, PBS and isotype-
matched negative antibody controls (except for IgG3 for which
PBS alone was used) and positive cytospin controls were included.
Expression of MAGE-1, -2, -3and -4 genes
Total RNA was isolated fromtissue samples by the guanidine isoth-
iocyanate-caesium chloride procedure. MAGE -1, -2, -3 and -4
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Figure 1 (A) Positive expression of stromal and carcinoma cells for the HLA-A locus (Al31 mAb). (B) Loss of HLA-A3 allelic expression by carcinoma cells of
the same patient as in (A), while surrounding stromal cells are positive for this allele (160-30 mAb). (DAB substrate, blue counterstain of haematoxylin,
magnification x 340)
gene expression was assessed by reverse transcription followed by
polymerase chain reaction (RT-PCR) amplification and ethidium
bromide staining. PCR products were then run on 2% agarose gels,
Southern blotted and probed with digoxigenin-labelled oligonu-
cleotides as previously described (Mulcahy et al 1996). The data
described in this paper are part of a larger study of MAGE gene
expression in HNSCC (manuscript in preparation).
RESULTS
A summary of the immunohistochemistry results obtained for
HLA expression in the 34 HNSCC specimens is shown in Table 3.
In the three normal mucosa specimens studied, the epithelia
expressed HLA class I molecules and ICAM-1 but not HLA-DR
(HLA class II).
HLA class I and TAP-1 expression
For the tumour specimens, heterogeneous class I expression, as
determined by W6/32 staining, was found in only 2 out of 34 (6%)
ofthe HNSCC tumours studied. Complete loss ofHLAclass I mole-
cules by tumour cells was not observed in this group of samples.
Heterogeneous expression of the 0B2-microglobulin molecule,
however, was detected in 4 out of34 (12%) ofthe cases stained.
Heterogeneous locus-specific expression of the HLA-A or -B
locus or both was observed in 5 out of 34 (15%) specimens.
Complete locus loss has not been detected.
Heterogeneous expression ofone or more HLA class I alleles by
the tumour cells was evident in 13 out of 34 (38%) cases. In addi-
tion, complete loss of an allele by carcinoma cells was detected in
8 out of 34 (24%) cases. An example of the staining patterns
observed for HLA class I allelic loss is shown in Figure 1. When
more than one monoclonal antibody that had the same specificity
was used, the staining patterns obtained were found to be similar.
It was also observed that certain class I alleles appear to be
down-regulated to a greater extent than others. For example,
comparing tumour cell expression of the HLA-B7 allele with that
ofHLA-B8 (which was found to be expressed by stromal cells at a
similar frequency in the specimens stained) and also of HLA-A3
with HLA-A1, defective expression ofHLA-B7 and HLA-A3 was
Table 4 HLA class expression in primary tumours and their associated
lymph node metastases
Patient Site of Grade Defects in HLA class I expression
number primary
Primary tumour Lymph node
metastasis
HN27 Tongue Poor Het HLA-B8 Loss B locus
Loss HLA-B8
Loss HLA-Bw4
Loss HLA-Bw6
Het HLA-A2
HN 36 Transglottis Moderate NAD NAD
(larynx)
HN 37 Parotid Poor Het HLA-B7 Het ,2m
Het B locus
Weak HLA-A2
Loss HLA-A3
Loss HLA-B7
HN 44 Oropharynx Moderate Loss HLA-A3 Loss HLA-A3
Loss HLA-B7 Loss HLA-B7
Het HLA-Bw4 Het HLA-Bw4
NAD, no abnormality detected; Het, heterogeneous expression on carcinoma
cells.
observed at a higher frequency than that ofthe HLA-B8 and HLA-
Al alleles respectively. In three cases in which a positive stromal
stain for HLA-B7 and HLA-B8 was obtained, the expression of
the HLA-B7 allele on the tumour cells was found to be down-
regulated, while the HLA-B8 allele was still present.
While there appears to be some contradictions in Bw4 and Bw6
reactivities with expression of Bw6 in cases that have lost Bw4
and B7 (which is Bw6 positive), this can be explained by the other
B allele being expressed and the cross-reactivity of Bw4 with
some A alleles.
In the four paired primary and lymph node cases, two out of the
four lymph node metastases had more defects in class I antigen
expression than theprimary lesions; the results are shown in Table4.
In total, 18 outof34 (53%) ofthe HNSCC specimens stained had
some defect ofHLA class I expression on the surface ofthe tumour
cells. However, high positive staining values for the expression of
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Table 5 Abberrant HLA class expression in relation to MAGE gene expression and p53 overexpression by HNSCC cells
No. of HN HLA class I HLA-DR MAGE-1, -2, -3, -4 p53
specimen abnormality expression gene expression by Overexpression
PCR
4 NAD Neg Neg Neg
8 NAD Neg 1, 4 +
10 Het A2, Neg A3 P Neg +++
11 Neg B7, Neg Bw4 Neg 4 +
12 Neg A3, Het A30/31, Het Bl7 Neg 1, 2, 4 +++
14 Het W6/32, Het J2m, Het Neg NA Neg
A/B loci, Het A2, Het Bw4
15 NAD Neg 1, 4 Neg
16 Neg A2 Het 50% 1 +
17 Het B7 Neg 3,4 ++
18 NAD Neg NA ±
19 Neg A3, Neg B7 Neg Neg ++
20 Het P2m Neg 2, 3, 4 ++
21 Het A locus, Het B/C P 4 ...
locus, Het A2
22 Het W6/32, HetP2m, Het Neg NA +++
A/B loci, Het B/c loci, Het B7
23 NAD Neg Neg +
25 NAD Neg Neg NA
26 HetP2m, Het B7 Neg NA Neg
27 Het B/C loci, Het B8 Neg 2, 3, 4 +
30 NAD Neg Neg +
31 NAD Neg Neg Neg
33 Het B7, Het Bw4 Het 60% 1, 2 NA
34 NAD Neg 1,3 Neg
36 NAD P 1 NA
37 Het B7 P Neg NA
38 Het A locus, Neg Al, Het Neg Neg +++
A2, Het B8, Neg Bw6
39 NAD Het 50% NA NA
42 NAD P Neg NA
43 NAD Neg 1, 2,3 NA
44 Neg A3, Neg B7, Het Bw4 Neg 1, 2, 3 NA
46 NAD P Neg NA
47 NAD P NA NA
48 Het Bw6 Het 50% Neg NA
49 NegA2 P 4 NA
53 NAD P NA NA
NAD, no abnormality detected; Neg, negative tumour; Het, heterogeneous tumour expression; P, positive tumour expression; NA,
information not available. For p53 staining: +++, strong diffuse nuclear stain in tumour cells; ++, intermediate stain; +, weak but diffuse
tumour nuclear stain; ± weak, patchy tumour stain; Neg, negative tumour nuclear stain, similar to negative control.
the TAP-I and TAP-2 transporter proteins associated with HLA
class I antigen processing were found. Heterogeneous expression of
TAP-I protein, but not of TAP-2, was detected in only 2 out of 34
(6%) of the cases. It was also noticed, however, that in these cases
defective expression ofthe HLA-A2 allele was also found.
ICAM-1 and HLA-DR expression in HNSCC
ICAM-1 expression on tumour cells was lost in 5 out of the 34
(15%) cases examined. A further 7 out of34 (21%) specimens had
heterogeneous expression of this molecule on their tumour cells.
Examples of positive and negative tumour staining for ICAM-1
are shown in Figure 2. De novo expression of HLA class II mole-
cules by HNSCC cells, determined by the use of an anti-HLA-DR
antibody, was found in 13 out of 34 (38%) specimens. Of these
cases, 4 out of 13 (31%) had heterogeneous expression of HLA-
DR, while the remaining 9 out of 13 (69%) were considered to be
highly positive. Examples ofabsent and de novo HLA-DR antigen
expression in HNSCC specimens are shown in Figure 2.
Correlations between HLA and ICAM-1 expression with
clinicopathological parameters
HLA class I loss, loss ofICAM-1 expression and de novo expres-
sion ofHLA-DR was found to occur atall sites from which tumour
specimens were obtained. No correlation could be found between
grade and stage of HNSCC with loss ofHLA class I and ICAM-1
expression, but this may be due to the skewed distribution of the
specimens. Decreased expression of these molecules occurred in
early as well as late stage lesions, which is highlighted by
the finding of HLA class I allelic loss in one borderline
dysplasia/carcinoma specimen. However, expression of HLA-DR
may be associated with well-differentiated tumours otherthan with
moderately/poorly differentiated tumours.
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Figure 2 (A) Negative expression of HLA-DR by carcinoma cells, in contrast to (B) showing positive de novo expression. (C) Positive expression of lCAM-1 by
both carcinoma and stromal cells, with (D) showing loss of this adhesion molecule by tumour cells in another HNSCC specimen (magnification x 340)
No correlations could be made between HLA and ICAM-1
expression with local lymph node involvement.
Expression of MAGEgenes and p53 in HNSCC
specimens
The expression oftheMAGE-1, -2, -3, -4 genes was determined by
reverse transcription PCR in 27 out of 34 HNSCC specimens.
Fifteen out of 27 (55.6%) of these tumour samples expressed at
least one of these genes. Expression of MAGE-] was found in 9
out of 15 (60%), MAGE-2 in 6 out of 15 (40%), MAGE-3 in 6 out
of 15 (40%) and MAGE-4 in 9 out of 15 (60%) tumour specimens
that were positive for MAGE.
Positive nuclear staining for overexpressed p53 protein was
detectedbyimmunohistochemistry in 15 outof21 (71%) specimens.
The expression of these tumour-associated antigens in relation
to loss of HLA class I alleles or de novo HLA-DR expression is
given in Table 5. Ten out of 15 (66%) tumours expressing MAGE
genes showed aberrant HLA expression. Eleven out of 15 (73%)
tumours showing strong staining for p53 demonstrated altered
expression of HLA class I expression compared with two out of
six (33%) cases in which p53 overexpression was not detected.
Discussion
With the use of allele-specific antibodies, this study of HLA class I
antigen expression in HNSCC has founddefects inallelicexpression
in 17 out of 34 (50%) ofthe specimens stained. However, in only 2
out of 34 (6%) cases was heterogeneous expression of HLA class I
detected when using the anti-HLA class I antibody W6/32.
Although a lower frequency of loss of W6/32 positivity was
found in this study compared with previous studies on HNSCC and
HLA class I expression (Esteban et al, 1989; Houck et al, 1990;
Mattijsen et al, 1991), which may be accounted forby differences in
the tumour samples used, the high frequency of aberrant allelic
expression detected implies that previous studies on HLA class I
expression using antibodies directed againstmonomorphic determi-
nants of these molecules may be underestimates. Using an even
widerpanel ofantibodies against these allele-specific determinants,
greater amounts ofaberrant expression may be detected.
Concordant expression ofHLA class I andP2m was observed in
all but two cases that showed heterogeneous P2m and no loss of
reactivity with W6/32. Uncoordinated expression of P2m and
heavy chains has also been observed in lung, colon and cervical
cancers (Momburg et al, 1989; Keating et al, 1995; Korkolopoulou
et al, 1996).
To account for the discrepancy between the expression of the
monomorphic 'framework' determinants ofHLA class Imolecules,
compared with the loss of specific HLA class I alleles, it has been
suggested that malignant cells may compensate for the loss of
one class I allospecificity by overexpressing the remaining ones
(Ferrone and Marincola, 1995). This may also help to account for
the differences in the expression ofcertain alleles on HNSCC cells,
with some alleles (HLA-B7, HLA-A3) being down-regulated to a
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much greater degree than others (HLA-B8, HLA-Al) on the
surface of tumour cells.
In cervical cancer, tumour cells that have decreased expression
of the HLA-B7 allele have been associated with a high propensity
for lymph node metastases and a poorer clinical outcome (Honma
et al, 1994; Ellis et al, 1995). It is thought that the expression ofthis
allele may be important in the control of HPV-associated carci-
noma, by playing a dominant role in the presentation of immuno-
genic HPV-derived peptides to cytotoxic T-cells (Ellis et al, 1995;
Keating et al, 1995). By decreasing the expression of this allele,
and possibly overexpressing other HLA class I alleles, then tumour
cells can decrease the density of immunogenic peptide-MHC
complexes on their cell surface to avoid recognition and stimula-
tion ofanti-tumour CTL responses (Rivoltini et al, 1995).
As the epithelial cells of the human upper aerodigestive tract
resemble those of the female cervical cavity, these cells are also
susceptible to HPV infection, with HPV proteins being detected in
30-40% of oral cancer specimens (Gujuluva et al, 1996).
Cytotoxic T-lymphocytes have also been isolated in vitro from
tumour-infiltrating lymphocytes within HNSCC biopsies, and they
demonstrate MHC class I restricted killing of HPV-infected SCC
cells (Hald et al, 1995). Whether the loss of the HLA-B7 allele in
HNSCC has prognostic implications similar to that in cervical
cancer has still to be determined. Because of the limited sample
size and follow-up data, no conclusions can be made from this
study. However, the greater amounts ofloss of HLA class I alleles
in two out of four of the lymph node metastases compared with
their associated primary tumours suggests that the loss of HLA
class I may have a role in the progression ofHNSCC.
The mechanisms behind down-regulated HLA class I expression
on the surface of tumour cells are multiple and include defects in
P2m, genetic loss of class I a-chains, gene rearrangements, altered
transcriptional control, oncogenic activation, viral proteins and
altered functions of TAP and proteasome subunits involved in the
antigen-processing pathway (Ferrone and Marincola 1995; Garrido
et al, 1995; Seliger et al, 1996). Although decreased expression of
TAP-I has been found to occur to a significant level in cervical,
lung and breast cancer (Cromme et al, 1994; Kaklamanis et al,
1995; Korkolopoulou et al, 1996), heterogeneous expression of
TAP-I was only found in 2 out of 34 HNSCC specimens stained in
this study. This high frequency ofTAP-I expression may be related
to the high levels of expression of HLA class I molecules detected
by W6/32, with the majority of allelic loss being due to other
mechanisms. It was noticed however that in the two specimens in
which heterogeneous expression of TAP-I was found, defective
expression ofthe HLA-A2 allele was also present.
The up-regulated expression of HLA-DR (HLA class II) was
found in 38 of the tumour specimens stained. Other studies on
HLA-DR expression in HNSCC give varying figures, ranging
from as low as 8% (Esteban et al, 1989) to as high as 70% (Houck
et al, 1990; Mattijssen et al, 1991). Previous reports have also
differed as to what type of tumour predominantly express HLA
class II molecules, with Esteban et al (1989) correlating HLA-DR
expression to well-differentiated tumours but with others stating
that class II positivity was associated mainly with poorly differen-
tiated tumours (Houck et al, 1990; Mattijssen et al, 1991). In this
study, although no correlations could be made regarding HLA-DR
positivity with site, stage and regional lymph node involvement, it
was observed that a high frequency of well-differentiated tumours
showed de novo expression of HLA-DR compared with moder-
ately/poorly differentiated HNSCC.
The functional significance of HLA class II molecules on
HNSCC cells is debatable, with de novo expression of HLA-DR
being related to the presence of cytokines (e.g. IFN-y, TNF-a)
released by tumour-infiltrating lymphocytes (Matsushita et al,
1996), the differentiation status of the cell or as a result of
oncogenic transformation. Samukawa (1993) has found a signifi-
cant CD8+CD3+T-cell infiltrate in head and neck carcinomas
expressing HLA-DR compared with a CD4+ CD3+ infiltrate in
HLA-DR-negative tumours. In vitro findings have also suggested
that both MHC class I and class II molecules expressed on
head and neck tumour cells play critical roles in inducing
tumour-specific CD8+ and CD4+ cytotoxic T-lymphocytes
(Chikamatsu et al, 1994).
The expression of ICAM-I was found to be aberrant in a signif-
icant proportion of the HNSCC tumour specimens stained. Down-
regulation of this intercellular adhesion molecule on the surface of
tumour cells makes them less susceptible to lysis by immune
effector cells (Vainky et al, 1995), which include not only cytotoxic
T-cells but also NK cells, LAK cells and antibody-dependent cyto-
toxicity mediated by monocytes and granulocytes (Springer,
1990). Hence, decreased ICAM-l expression may serve as an
additional immunological escape mechanism by tumour cells.
Altered ICAM-1 expression may also affect the interaction
between tumour cells and the surrounding matrix, as ICAM-1
interacts with fibrinogen and the extracellular matrix factor
hyaluronan (van de Stolpe and van der Saag, 1996). By affecting
attachment to the surrounding stroma, altered ICAM-1 expression
may be an important factor in the development of metastases;
although, in this study, no correlation was found between
decreased ICAM-l expression on HNSCC cells in relation to
regional lymph node involvement.
For the presentation of tumour antigens to the immune system,
the expression of HLA class I molecules by tumour cells, as well
as the antigen, is needed. With the isolation of antigenic peptides
derived from tumour antigens that bind to HLA class I molecules,
clinical trials of peptide-based cancer vaccines have started
(Marchand et al, 1995). Although the HLA type of the patient is
usually determined from a blood sample, the decreased expression
of specific HLA alleles on the tumour cell surface however may
mean that the tumour no longer expresses the restricting HLA
class I allele. Thus, the patient's tumour cells will no longer
present the antigenic peptide against which a peptide vaccine tries
to induce an immune response.
Table 5 demonstrates that although a patient's tumour may
express the tumour-associated antigens p53 andMAGEgenes, HLA
class I allele expression can frequently be deviant. In the case ofp53
overexpression, over70% ofcases harboured HLA aberration. Both
p53- and MAGE gene-encoded peptides are potential targets for
immune attack (Wiedenfeldetal, 1994; Boonet al, 1995) andloss of
presenting HLA molecules may influence processing of immuno-
genic peptides and consequent immune recognition. Hence, HLA
typing of the tumour itself, as well as the patient's blood, may be
needed to determine whether the necessary HLA alleles are
expressed. Also, a multi-peptide vaccine strategy using different
HLA class I alleles binding different antigenic peptides needs to be
sought to avoid the 'immunoselection' ofthese antigen-loss variants
(Lehmann et al, 1995; Maeureret al, 1996). Othermethods ofvacci-
nation must also be devised that can effectively trigger an anti-
tumour response. For example, genetically modified bacteria or
antigen-presenting cells, presenting a wide array of immunogenic
peptide-MHC complexes and co-stimulatory molecules on theircell
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surface, as well as secreting cytokines locally atthe tumoursite, may
produce along-lived, multi-pronged CTL attack (Irvine and Restifo,
1995).
The role of cytokines, such as TNF-ax and IFN-y, may also be
useful in the adjuvant setting because oftheir ability to up-regulate
MHC class I and ICAM-1 and also to induce MHC class II expres-
sion (Farrar and Schreiber, 1993; Scher et al, 1993; Ishii et al,
1994), especially if these molecules are associated with the
production of anti-tumour CTLs and a better prognosis for head
and neck cancer patients.
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